(Q38576124)

4 September 2017

Multimodal imaging in Alzheimer's disease: validity and usefulness for early detection (English)

1 reference

4 September 2017

0 references

1 reference

9

1 reference

4 September 2017

2

Alexander Drzezga

0 references

Jochen René Thyrian

Jochen René Thyrian

11

0 references

Michel J. Grothe

Michel J Grothe

3

0 references

Chris Fox

Chris Fox

12

0 references

Stefan J Teipel

1

Stefan Teipel

1 reference

4 September 2017

6

Norbert Schuff

1 reference

4 September 2017

15

Andreas Fellgiebel

1 reference

4 September 2017

8

Enrica Cavedo

1 reference

4 September 2017

14

Osama Sabri

1 reference

4 September 2017

4

Henryk Barthel

1 reference

4 September 2017

Gaël Chételat

5

1 reference

4 September 2017

Pawel Skudlarski

7

1 reference

4 September 2017

Wolfgang Hoffmann

10

1 reference

4 September 2017

Satoshi Minoshima

13

1 reference

4 September 2017

26 August 2015

1 reference

4 September 2017

1 reference

4 September 2017

14

1 reference

4 September 2017

10

1 reference

4 September 2017

1037-1053

1 reference

Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria

4 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Functional network disruption in the degenerative dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Selectively and progressively disrupted structural connectivity of functional brain networks in Alzheimer's disease - revealed by a novel framework to analyze edge distributions of networks detecting disruptions with strong statistical evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

A European multicentre PET study of fibrillar amyloid in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Tau imaging: early progress and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Use of Florbetapir-PET for Imaging β-Amyloid Pathology

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Conversion of amyloid positive and negative MCI to AD over 3 years: an 11C-PIB PET study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

In vivo fibrillar beta-amyloid detected using [11C]PiB positron emission tomography and neuropathologic assessment in older adults

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Absence of Pittsburgh compound B detection of cerebral amyloid beta in a patient with clinical, cognitive, and cerebrospinal fluid markers of Alzheimer disease: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

11C-PiB PET studies in typical sporadic Creutzfeldt-Jakob disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Correspondence between in vivo (11)C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Positron emission tomography imaging and clinical progression in relation to molecular pathology in the first Pittsburgh Compound B positron emission tomography patient with Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Positive florbetapir PET amyloid imaging in a subject with frequent cortical neuritic plaques and frontotemporal lobar degeneration with TDP43-positive inclusions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

[(18)F]Flutemetamol PET imaging and cortical biopsy histopathology for fibrillar amyloid β detection in living subjects with normal pressure hydrocephalus: pooled analysis of four studies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Positron emission tomography and neuropathologic estimates of fibrillar amyloid-β in a patient with Down syndrome and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Predictive accuracy of amyloid imaging for progression from mild cognitive impairment to Alzheimer disease with different lengths of follow-up: a meta-analysis. [Corrected

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Comparing predictors of conversion and decline in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Automated analysis of FDG PET as a tool for single-subject probabilistic prediction and detection of Alzheimer's disease dementia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Medial temporal lobe atrophy on MRI scans and the diagnosis of Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Visual assessment of medial temporal atrophy on MR films in Alzheimer's disease: comparison with volumetry

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Application of automated medial temporal lobe atrophy scale to Alzheimer disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Combining early markers strongly predicts conversion from mild cognitive impairment to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Morphological hippocampal markers for automated detection of Alzheimer's disease and mild cognitive impairment converters in magnetic resonance images.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

MRI hippocampal and entorhinal cortex mapping in predicting conversion to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Is radiological evaluation as good as computer-based volumetry to assess hippocampal atrophy in Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Fully automatic hippocampus segmentation and classification in Alzheimer's disease and mild cognitive impairment applied on data from ADNI

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Biomarker-based prediction of progression in MCI: Comparison of AD signature and hippocampal volume with spinal fluid amyloid-β and tau

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Automated cross-sectional and longitudinal hippocampal volume measurement in mild cognitive impairment and Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Prediction of Alzheimer's disease in subjects with mild cognitive impairment from the ADNI cohort using patterns of cortical thinning

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Predicting AD conversion: comparison between prodromal AD guidelines and computer assisted PredictAD tool

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Prediction of Alzheimer's disease and mild cognitive impairment using cortical morphological patterns

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Individual subject classification for Alzheimer's disease based on incremental learning using a spatial frequency representation of cortical thickness data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

BrainAGE in Mild Cognitive Impaired Patients: Predicting the Conversion to Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Machine learning framework for early MRI-based Alzheimer's conversion prediction in MCI subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Fornix integrity and hippocampal volume predict memory decline and progression to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Brain microstructure reveals early abnormalities more than two years prior to clinical progression from mild cognitive impairment to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Diffusion tensor imaging surpasses cerebrospinal fluid as predictor of cognitive decline and medial temporal lobe atrophy in subjective cognitive impairment and mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Predicting conversion to dementia in mild cognitive impairment by volumetric and diffusivity measurements of the hippocampus.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Individual prediction of cognitive decline in mild cognitive impairment using support vector machine-based analysis of diffusion tensor imaging data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Abnormal whole-brain functional connection in amnestic mild cognitive impairment patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Default mode network connectivity in stable vs progressive mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Predicting future clinical changes of MCI patients using longitudinal and multimodal biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Fluorodeoxyglucose-positron-emission tomography, single-photon emission tomography, and structural MR imaging for prediction of rapid conversion to Alzheimer disease in patients with mild cognitive impairment: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Accurate multimodal probabilistic prediction of conversion to Alzheimer's disease in patients with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Characterizing Alzheimer's disease using a hypometabolic convergence index

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Binary classification of ¹⁸F-flutemetamol PET using machine learning: comparison with visual reads and structural MRI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression from mild cognitive impairment to Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Diagnostic accuracy of 18 F-FDG and 11 C-PIB-PET for prediction of short-term conversion to Alzheimer's disease in subjects with mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Reducing between scanner differences in multi-center PET studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Positron emission tomography in evaluation of dementia: Regional brain metabolism and long-term outcome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Brain amyloid imaging--FDA approval of florbetapir F18 injection.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Relationship between hippocampal volume and CA1 neuron loss in brains of humans with and without Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Antemortem MRI findings correlate with hippocampal neuropathology in typical aging and dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Measurements of the amygdala and hippocampus in pathologically confirmed Alzheimer disease and frontotemporal lobar degeneration

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Automatic classification of MR scans in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

MRI of hippocampus and entorhinal cortex in mild cognitive impairment: a follow-up study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: results from ADNI.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Screening for dementia - is it a no brainer?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Alzheimer's disease as a disconnection syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Diffusion tensor imaging detects and differentiates axon and myelin degeneration in mouse optic nerve after retinal ischemia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Multicenter stability of diffusion tensor imaging measures: a European clinical and physical phantom study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Toward discovery science of human brain function

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Intrinsic functional component analysis via sparse representation on Alzheimer's disease neuroimaging initiative database

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Functional connectivity in autosomal dominant and late-onset Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Neurophysiological investigation of spontaneous correlated and anticorrelated fluctuations of the BOLD signal

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

New MRI markers for Alzheimer's disease: a meta-analysis of diffusion tensor imaging and a comparison with medial temporal lobe measurements

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Resting-state functional MR imaging: a new window to the brain

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

The power of neuroimaging biomarkers for screening frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Regularization and variable selection via the elastic net

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

The relative importance of imaging markers for the prediction of Alzheimer's disease dementia in mild cognitive impairment - Beyond classical regression

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Pittsburgh compound B imaging and prediction of progression from cognitive normality to symptomatic Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

An operational approach to National Institute on Aging-Alzheimer's Association criteria for preclinical Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Brain injury biomarkers are not dependent on β-amyloid in normal elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Alzheimer disease: Aβ-independent processes-rethinking preclinical AD.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Imaging markers for Alzheimer disease: which vs how

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Clinical and biomarker changes in dominantly inherited Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

New research criteria for the diagnosis of Alzheimer's disease applied in a memory clinic population.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

The new Alzheimer's criteria in a naturalistic series of patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Impact of molecular imaging on the diagnostic process in a memory clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Fluorodeoxyglucose-positron emission tomography in the differential diagnosis of early-onset dementia: a prospective, community-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Do general practitioners recognize mild cognitive impairment in their patients?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Rates of formal diagnosis in people screened positive for dementia in primary care: results of the DelpHi-Trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Implementing a screening and diagnosis program for dementia in primary care

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Bringing forward the diagnosis of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Phases of biomarker development for early detection of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Potential impact of amyloid imaging on diagnosis and intended management in patients with progressive cognitive decline

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

Life- and person-centred help in Mecklenburg-Western Pomerania, Germany (DelpHi): study protocol for a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2815%2900093-9

7 January 2021

10.1016/S1474-4422(15)00093-9

Identifiers

DOI

1 reference

4 September 2017

1 reference